Amal Therapeutics Report issue

For profit Phase 1 Phase 2
Founded: Geneva Switzerland (2012)
Status: Acquired by Boehringer Ingelheim (2019)

Organization Overview

First Clinical Trial
2019
NCT04046445
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Amal Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (2)

atp128 (1 trial)

bi 754091 (2 trials)

Drugs in Phase 1 Trials (3)

atp150 (1 trial)

atp152 (1 trial)

vsv-gp154 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Rectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 5